The FDA approves Akorn's (NASDAQ: AKRX ) betamethasone dipropionate lotion USP (augmented), 0.05%, a topical corticosteroid for the treatment of inflammatory skin conditions. More news on: Akorn, Inc., Healthcare stocks news, Stocks on the move, Read more ...

LAKE FOREST, Ill., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for betamethasone diprop...

LAKE FOREST, Ill., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that it plans to issue a press release before market open on Thursday, October 31, 2019 outlining its third quarter 2019 financial resu...